- Maurizio Fava, MD
- Jerrold F. Rosenbaum, MD
Description
The Virtual Grand Rounds Series provides your institution with consistent, high-quality, one-hour educational programs, presented by the Massachusetts General Hospital Psychiatry Academy’s world-renowned faculty. Led by Program Directors Jerrold F. Rosenbaum, MD, Psychiatrist in Chief at Massachusetts General Hospital, and Maurizio Fava, MD, Executive Vice Chair of the Psychiatry Dept. at Massachusetts General Hospital, the Virtual Grand Rounds Series allows doctors, residents, and medical students to conveniently acquire knowledge about clinical challenges and innovative treatment options for a variety of psychiatric disorders.
Given the time constraints of today's clinical practice, the online format of the Virtual Grand Rounds Series means your medical staff can participate in real-time or choose to view the archived version whenever time allows. When viewed in live format, interactive features are enabled that let program faculty provide live feedback to questions and communicate directly with you and your staff.
Learning Objectives
|
Date |
Grand Rounds |
Learning Objectives |
|
7/13/2011 |
Rethinking Challenging Kids Stuart Ablon, Ph.D. |
-Discuss how lagging cognitive skills contribute to challenging behavior and how to use a collaborative problem solving process to reduce such behavior. -Explain how to structure the initial sessions of treatment when implementing a collaborative problem solving approach in therapy with challenging kids. |
|
7/20/2011 |
Man’s Oldest Friend and Oldest Enemy: Why We Should Bother Detecting Alcohol Use Among our Psychiatric Patients John F. Kelly, Ph.D. |
-List at least three important reasons why screening for alcohol use among psychiatric patients is critical to ensure quality care and be able to name and use at least two validated alcohol screening tools. -Describe the nature and elements of effective brief interventions for alcohol-related problems and make effective linkages to alternate levels of care.
|
|
8/3/2011 |
Role of Glutamatergic Drugs in Schizophrenia Dost Ongür, M.D., Ph.D. |
-Describe the role of glutamatergic abnormalities in the pathogenesis of schizophrenia. -Describe current efforts at drug development focusing on the glutamate system in schizophrenia. |
|
8/17/2011 |
Complementary and Alternative Medicine in Women Across the Reproductive Lifespan Marlene P. Freeman, M.D. |
-Describe the prevalence of Complementary and Alternative Medicine use in the US and in women. -Understand considerations around CAM treatments during pregnancy and other reproductive events in women. |
Faculty
-
Director, Think:Kids, Department of Psychiatry, MGH
Director, Psychotherapy Research Program, MGH
Associate Clinical Professor of Psychology in the Department of Psychiatry, Harvard Medical School -
Executive Vice Chair, Department of Psychiatry, MGH
Executive Director, Clinical Trials Network & Institute (CTNI), MGH
Director, Depression Clinical & Research Program, MGH
Slater Family Professor of Psychiatry, Harvard Medical School -
Associate Medical Director, Clinical Trials Network & Institute, MGH
Director of Clinical Services, Perinatal and Reproductive Psychiatry Program, MGH
Associate Professor of Psychiatry, Harvard Medical School -
Co-Director, MGH Postgraduate Medical Education
Assistant Clinical Professor of Psychiatry, Harvard Medical School -
Associate Director, Center for Addiction Medicine, MGH
Program Director, Addiction Recovery Management Service, MGH
Associate Professor of Psychology, Department of Psychiatry, Harvard Medical School -
Clinical Director of Psychotic Disorders Division, McLean Hospital
Assistant Professor of Psychiatry, Harvard Medical School -
Psychiatrist in Chief, Massachusetts General Hospital
Stanley Cobb Professor of Psychiatry, Harvard Medical School
CME Information
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital and the Massachusetts General Hospital Psychiatry Academy. McLean Hospital is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Credit Designation
McLean Hospital designates this continuing medical educational activity for a maximum of 1 AMA PRA Category 1 Credit(TM). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.
Social Workers
This Grand Rounds has been approved in accordance with the regulations of the Board of Registration of Social Workers, 258 CMR 31.00.
J. Stuart Ablon, PhD
No disclosures indicated.
Last updated: 7/27/2010
Maurizio Fava, MD
Research Support
Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bio Research, BrainCells Inc., Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, Eli Lilly & Co., Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J&J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab LLC, Pfizer Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals Inc., Synthelabo, and Wyeth-Ayerst Laboratories
Speaking/Publishing
Advanced Meeting Partners, American Psychiatric Association, Astra-Zeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly & Co., Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex , Novartis, Organon Inc., Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, Wyeth-Ayerst Laboratories
Advisory/Consulting
Abbott Laboratories, Amarin, Aspect Medical Systems , Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management Inc, Biovail Pharmaceuticals Inc., BrainCells Inc, Bristol-Myers Squibb, Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Co., EPIX Pharmaceuticals, Fabre-Kramer, Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceuticals, Jazz Pharmaceuticals, J&J Pharmaceuticals, Knoll Pharmaceuticals, Labopharm , Lorex Pharmaceuticals, Lundbeck , MedAvante Inc. Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab LLC, Pfizer Inc , PharmaStar , Pharmavite , Precision Human Biolaboratory, Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals Inc., Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, and Wyeth-Ayerst Laboratories
Equity Holdings
Compellis
Royalty/Patent, Other Income
Patent applications for SPCD and for a combination of azapirones and bupropion in MDD, copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER
Last updated: 7/27/2010
Marlene P. Freeman, MD
Research Support
Forest, GlaxoSmithKline, and Eli Lilly & Co.
Advisory/Consulting
PamLab LLC, Reliant, and Omegabrite
CME Program Support
Forest, KV Pharmaceuticals, and AstraZeneca
Last updated: 7/27/2010
John A. Fromson, MD
Dr. Fromson has indicated that neither he nor any member of his immediate family has a significant financial interest or affiliation with the manufacturer of a commercial product or provider of a commercial service.
Last updated: 1/3/2012
John F. Kelly, PhD
No disclosures indicated.
Last updated: 7/27/2010
Dost Ongür, MD, PhD
No disclosures indicated.
Last updated: 7/27/2010
Jerrold F. Rosenbaum, MD
Speaking/Honoraria
Boehringer-Ingelheim, BMS, Cyberonics, Forest, Lilly, Reed Elsevier, and Schwartz.
Advisory/Consulting
Auspex, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Compellis, Cyberonics, EPIX, Forest, GSK, Janssen, Lilly, MedAvante, Neuronetics, Novartis, Orexigen, Organon, Pfizer, Roche Diagnostics, Sanofi, Shire, Somaxon, Somerset, Sepracor, Supernus, and Wyeth.
Equity Holdings
Compellis, Medavante, Somaxon, and Supernus.
Last updated: 7/27/2010